Skip to main content

Table 2 Lack of correlation between pDNA assessed by GENEQUANT and by NANOVUE

From: Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer

SAMPLE

GENEQUANT

Average NANOVUE

SAMPLE

GENEQUANT

Average NANOVUE

NUMBER

[ ] pDNA1

[ ] pDNA1,2

NUMBER

[ ] pDNA1

[ ] pDNA1,2

1

0.2

55

27

4.2

36.75

2

0.25

111.5

28

4.93

48.5

3

0.33

36.5

29

5.6

51

4

0.6

88.25

30

5.73

132.5

5

0.63

25.75

31

6.5

61

6

0.63

131.5

32

6.77

92.5

7

0.67

144.5

33

6.9

155.75

8

0.76

66.5

34

7.13

28.75

9

1

50.25

35

7.27

90

10

1.2

66.75

36

7.8

136

11

1.3

48

37

7.87

53.5

12

1.3

68

38

7.87

133.75

13

1.3

66.25

39

7.97

115.5

14

1.4

80.25

40

8.87

32.25

15

1.47

81.75

41

10.5

81.5

16

1.6

93.5

42

11.2

107.45

17

1.7

49

43

11.3

197.25

18

2

141.25

44

11.6

131.75

19

2.1

55.5

45

12.3

45.75

20

2.1

69.5

46

13.2

52.5

21

2.1

69.75

47

15.8

64.5

22

2.2

140.5

48

17.37

79.5

23

3.03

163.5

49

17.8

87

24

3.37

27.25

50

20.7

125.5

25

3.37

66

51

23

46.25

26

4.17

179.75

   
  1. 1 μg/mL; 2Average between duplicates.